





## Follow-up March BOT Meeting: Financial Impact of the Enhanced Blood Glucose Test Strip Benefit

**Board of Trustees Meeting** 

May 24, 2013

A Division of the Department of State Treasurer


## Review of Diabetic Test Strip Enhancement

- On March 22, 2013 the Board approved an increase in the number of blood glucose test strips available by prescription to plan members with diabetes
  - For insulin dependent members, the limit was increased from 153 to 204 strips/30 days
  - For non-insulin dependent members with diabetes, the limit was increased from 51 to 102 strips/30 days
- The Board was presented initial estimates of the financial impact on the Plan, which calculated the impact if all test strip users increased to the new maximum
  - \$3.9 million for insulin dependent members
  - \$2.1 million for non-insulin dependent members
- Plan staff reported in March that a refined analysis would be conducted with the Plan's actuaries (Segal) to estimate the financial impact of the enhancement



## 2012 Blood Glucose Test Strip Costs

- Express Scripts (ESI) provided data on prescriptions for blood glucose test strips during calendar 2012
- 2012 costs:
  - Gross costs for nearly 7,000 insulin dependent test strip users averaged \$570 PMPY
  - Gross costs for non-insulin dependent test strip users averaged \$185 PMPY
- ESI's initial estimate would represent a doubling of the 2012 cost of prescription test strips for Plan members



## Conclusion

- After reviewing the initial estimates, Segal suggested a cost estimation model focused on test strip users at or near the previous limits (those in place prior to March 22, 2013 Board meeting)
- A review of the 2012 data suggests that no more than 10-15% of test strip users were at or above 80% of the previous test strip maximum
- Segal also noted that the data set suggests that some members may have been exceeding the prior limits due to a discrepancy in the way the test strips were prescribed and the way the prescriptions were filled

• Segal concluded that the new test strip maximums will result in additional pharmacy costs for the Plan of \$500,000 to \$1,500,000

Although some members may currently be using

- Although some members may currently be using medical benefits to purchase test strips (subject to deductible and coinsurance), Segal does not anticipate a measurable reduction in medical claims with the enhancement to the pharmacy benefit
- To be conservative, Segal will use an estimated increase in pharmacy costs of \$1.5 million in Plan projections

